Oligospermia
Conditions
Interventions
Experimental Group:Take 4 ergothioneine capsules daily, two in the morning and two in the evening, for 90 consecutive days.
Control group:Placebo
Sponsors
Shulan (Hangzhou) Hospital
Eligibility
Sex/Gender
All
Age
25 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1.Male subjects aged 25 to 50; 2. Poor sperm motility. At least two standardized semen analyses both indicate: 10%=15×10^6 cells /ml; The normal sperm morphology rate is greater than or equal to 4%. 4. No other Chinese or Western medicines for treating oligospermia, asthenospermia or teratospermia have been taken in the past three months. 5. No nocturnal emission, masturbation or sexual intercourse occurred within three days before the screening of the subjects. 6. Those who are married or have a stable sexual partner and whose partner can cooperate with the trial and fill out the questionnaire; 7. Agree and sign the informed consent form
Exclusion criteria
Exclusion criteria: 1.Patients with severe neurological and mental system diseases, psychological disorders or abnormal hormone levels; 2. Patients with severe liver and kidney dysfunction, hypertension, coronary heart disease, diabetes, and those who are clearly allergic to the drugs used in this study; 3. Congenital factors and grade III varicocele; 4. Patients with acute or chronic inflammation of the urinary system, abnormal libido, seminal tract obstruction, organic lesions of the testicles or other sexual dysfunction diseases such as abnormal penile erection; 5. Azoospermia; Sperm does not liquefy. Abnormalities of male reproductive organs; Ejaculation dysfunction; 6. Patients with a history of genital trauma or surgery, abnormal genital development or genital malformations; 7. Patients who have received treatment related to enhancing sperm motility in the past month; 8. Patients with a long history of alcohol abuse or drug abuse; 9. Those who have received vaccination within one month prior to screening (special: at least one month for COVID-19 adenovirus vector vaccines, and at least two weeks for inactivated and recombinant vaccines), or those who plan to receive vaccination during the study period; 10. Those who have participated in other clinical trials in the past three months; 11. The researcher deems it inappropriate to participate in the clinical trial or is unable to complete this research for other reasons
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Sperm motility;Sperm DNA Fragmentation Index;Sperm morphology;Testosterone;Self-Esteem and Sexual Relationships Questionnaire (SEAR); | — |
Countries
China
Contacts
Public ContactWu Lihua;Zhong Chao
Shulan (Hangzhou) Hospital
Outcome results
None listed